Immunoprecise Short Long Term Debt vs Total Current Assets Analysis
IPA Stock | USD 1.18 0.06 5.36% |
Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Short Long Term Debt and its Total Current Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
Short Long Term Debt vs Total Current Assets
Short Long Term Debt vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Short Long Term Debt account and Total Current Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Immunoprecise Antibodies' Short Long Term Debt and Total Current Assets is 0.49. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Short Long Term Debt and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Immunoprecise Antibodies are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Short Long Term Debt i.e., Immunoprecise Antibodies' Short Long Term Debt and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.49 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Immunoprecise Antibodies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.The current year's Selling General Administrative is expected to grow to about 23.9 M, whereas Tax Provision is projected to grow to (1 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 11.0M | 11.6M | 13.3M | 14.0M | Total Revenue | 19.4M | 20.7M | 23.8M | 25.0M |
Immunoprecise Antibodies fundamental ratios Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Liab | 1.8M | 964K | 1.3M | 441K | 507.2K | 558.1K | |
Total Current Liabilities | 7.9M | 6.1M | 9.3M | 5.9M | 6.8M | 7.1M | |
Total Stockholder Equity | 15.1M | 56.9M | 75.3M | 57.8M | 66.5M | 69.8M | |
Property Plant And Equipment Net | 3.2M | 4.1M | 3.7M | 10.7M | 12.3M | 12.9M | |
Net Debt | 1.9M | (38.3M) | (27.4M) | (1.0M) | (911.7K) | (957.3K) | |
Retained Earnings | (22.5M) | (29.8M) | (46.5M) | (73.1M) | (65.8M) | (62.5M) | |
Accounts Payable | 1.8M | 3.0M | 4.8M | 3.4M | 3.9M | 4.1M | |
Cash | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Non Current Assets Total | 19.6M | 18.1M | 56.0M | 61.0M | 70.2M | 73.7M | |
Cash And Short Term Investments | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Net Receivables | 3.7M | 4.1M | 3.4M | 4.4M | 5.1M | 5.3M | |
Common Stock Shares Outstanding | 13.6M | 16.5M | 19.7M | 24.9M | 28.6M | 30.1M | |
Liabilities And Stockholders Equity | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Assets | 614.0K | 2.3M | 2.8M | 2.6M | 3.0M | 3.1M | |
Other Stockholder Equity | 3.5M | 6.6M | 7.3M | 10.8M | 9.7M | 9.2M | |
Total Liab | 12.2M | 10.0M | 18.2M | 20.0M | 23.0M | 24.2M | |
Total Current Assets | 7.7M | 48.9M | 37.5M | 16.8M | 19.3M | 20.3M | |
Non Current Liabilities Total | 4.2M | 4.0M | 8.9M | 14.1M | 16.2M | 17.0M | |
Non Currrent Assets Other | 85.1K | 79K | 82K | 86K | 77.4K | 73.5K | |
Short Long Term Debt Total | 4.5M | 3.5M | 2.5M | 7.3M | 8.4M | 8.8M | |
Property Plant And Equipment Gross | 3.1M | 4.1M | 9.4M | 17.1M | 19.6M | 20.6M | |
Accumulated Other Comprehensive Income | (300.2K) | (687K) | (2.5M) | 2.6M | 2.4M | 2.5M | |
Short Term Debt | 2.9M | 986K | 2.2M | 1.1M | 1.3M | 1.0M | |
Inventory | 818.6K | 1.2M | 1.6M | 2.1M | 2.4M | 2.5M | |
Current Deferred Revenue | 1.5M | 1.1M | 1.0M | 977K | 1.1M | 567.8K | |
Intangible Assets | 8.3M | 6.1M | 32.4M | 30.9M | 35.6M | 37.3M | |
Common Stock | 34.1M | 80.1M | 114.6M | 117.5M | 135.1M | 141.8M | |
Net Tangible Assets | (1.0M) | 43.1M | 23.2M | 7.7M | 8.9M | 12.5M | |
Net Invested Capital | 17.7M | 58.5M | 76.6M | 57.8M | 66.5M | 39.4M | |
Net Working Capital | (230.3K) | 42.8M | 28.2M | 10.9M | 12.5M | 13.7M | |
Property Plant Equipment | 3.1M | 4.0M | 3.3M | 10.4M | 12.0M | 12.5M | |
Other Liab | 2.6M | 1.5M | 8.6M | 7.9M | 9.1M | 5.1M | |
Other Assets | 287.6K | 163K | 476K | 437K | 393.3K | 373.6K | |
Good Will | 7.9M | 7.8M | 19.7M | 19.2M | 22.0M | 12.4M | |
Capital Lease Obligations | 1.9M | 1.9M | 1.2M | 7.3M | 8.4M | 8.8M | |
Long Term Investments | 118.9K | 111K | 142K | 115K | 132.3K | 122.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Stocks Directory Find actively traded stocks across global markets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.42) | Revenue Per Share 0.939 | Quarterly Revenue Growth 0.203 | Return On Assets (0.11) | Return On Equity (0.26) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.